Matthew D. Vesely

Matthew D. Vesely

Auto-generated profile, based on publicly available information

Matthew D. Vesely

Department of Dermatology, Yale School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2011 in Annual Review of Immunology
Verified
Journal Article
Closed access
MVMatthew D. Vesely
Matthew D. Vesely
Michael KershawMichael Kershaw
Michael Kershaw
RSRobert D. Schreiber
Robert D. Schreiber
MSMark J. Smyth
Mark J. Smyth
The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against cancer. Recently, data obtained from numerous investigations in mouse models of cancer and in humans with cancer offer compelling evidence that particular innate and adaptive immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor-suppressor mechanisms. However, the immune system can also promote tumor progression. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. In this review, we discuss the current experimental and human clinical data supporting a cancer immunoediting process that provide the fundamental basis for further study of immunity to cancer and for the rational design of immunotherapies against cancer.

26 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
MGMatthew M. Gubin
Matthew M. Gubin
XZXiuli Zhang
Xiuli Zhang
HSHeiko Schuster
Heiko Schuster
ECEtienne Caron
Etienne Caron
JWJeffrey P. Ward
Jeffrey P. Ward
RSRobert D. Schreiber
Robert D. Schreiber
A carcinogen-induced mouse tumour model is used here to show that mutant tumour-specific antigens are targets for CD8+ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy, and that these antigens can be used effectively in therapeutic vaccines; this advance potentially opens the door to personalized cancer vaccines. In many individuals, immunosuppression is mediated by T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), immunomodulatory receptors expressed on T cells. Matthew Gubin et al. use the MCA mouse sarcoma model to show that mutant tumour antigens serve as targets for CD8+ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy with anti-PD-1 and/or anti-CTLA-4. The authors demonstrate that these antigens can be used effectively in therapeutic vaccines, suggesting a possible route to personalized cancer vaccines. The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts tumour cell immunogenicity1,2,3,4,5,6, but also as an extrinsic tumour suppressor that either destroys developing tumours or restrains their expansion1,2,7. Yet, clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of cancer-induced immunosuppression. In many individuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptors expressed on T cells8,9. Monoclonal-antibody-based therapies targeting CTLA-4 and/or PD-1 (checkpoint blockade) have yielded significant clinical benefits—including durable responses—to patients with different malignancies10,11,12,13. However, little is known about the identity of the tumour antigens that function as the targets of T cells activated by checkpoint blockade immunotherapy and whether these antigens can be used to generate vaccines that are highly tumour-specific. Here we use genomics and bioinformatics approaches to identify tumour-specific mutant proteins as a major class of T-cell rejection antigens following anti-PD-1 and/or anti-CTLA-4 therapy of mice bearing progressively growing sarcomas, and we show that therapeutic synthetic long-peptide vaccines incorporating these mutant epitopes induce tumour rejection comparably to checkpoint blockade immunotherapy. Although mutant tumour-antigen-specific T cells are present in progressively growing tumours, they are reactivated following treatment with anti-PD-1 and/or anti-CTLA-4 and display some overlapping but mostly treatment-specific transcriptional profiles, rendering them capable of mediating tumour rejection. These results reveal that tumour-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.

8 February 2012 in Nature
Verified
Journal Article
Open access
PDF file
HMHirokazu Matsushita
Hirokazu Matsushita
MVMatthew D. Vesely
Matthew D. Vesely
DKDaniel C. Koboldt
Daniel C. Koboldt
CRCharles G. Rickert
Charles G. Rickert
RURavindra Uppaluri
Ravindra Uppaluri
RSRobert D. Schreiber
Robert D. Schreiber
Exome analysis of chemical-carcinogen-induced mouse tumours provides evidence for T-cell-mediated immunoselection as a mechanism of immunoediting. Two groups reporting in this issue of Nature use contrasting approaches to come to many of the same conclusions about the process of cancer immunoediting, in which an individual is protected from cancer though the elimination and immunogenic modification of cancerous cells. Matsushita et al. use whole-exon sequencing of mouse sarcomas induced by chemical carcinogens to obtain evidence for T-cell-mediated immuno-selection as a mechanism of immune editing. DuPage et al. demonstrate that immunosurveillance and immunoediting can occur in an oncogene-driven endogenous tumour model provided that the tumours carry strong neoantigens that are not present in the host. Cancer immunoediting, the process by which the immune system controls tumour outgrowth and shapes tumour immunogenicity, is comprised of three phases: elimination, equilibrium and escape1,2,3,4,5. Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. A central tenet of cancer immunoediting is that T-cell recognition of tumour antigens drives the immunological destruction or sculpting of a developing cancer. However, our current understanding of tumour antigens comes largely from analyses of cancers that develop in immunocompetent hosts and thus may have already been edited. Little is known about the antigens expressed in nascent tumour cells, whether they are sufficient to induce protective antitumour immune responses or whether their expression is modulated by the immune system. Here, using massively parallel sequencing, we characterize expressed mutations in highly immunogenic methylcholanthrene-induced sarcomas derived from immunodeficient Rag2−/− mice that phenotypically resemble nascent primary tumour cells1,3,5. Using class I prediction algorithms, we identify mutant spectrin-β2 as a potential rejection antigen of the d42m1 sarcoma and validate this prediction by conventional antigen expression cloning and detection. We also demonstrate that cancer immunoediting of d42m1 occurs via a T-cell-dependent immunoselection process that promotes outgrowth of pre-existing tumour cell clones lacking highly antigenic mutant spectrin-β2 and other potential strong antigens. These results demonstrate that the strong immunogenicity of an unedited tumour can be ascribed to expression of highly antigenic mutant proteins and show that outgrowth of tumour cells that lack these strong antigens via a T-cell-dependent immunoselection process represents one mechanism of cancer immunoediting.

13 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAlexander X. Lozano
Alexander X. Lozano
ACAadel A. Chaudhuri
Aadel A. Chaudhuri
ANAishwarya Nene
Aishwarya Nene
ABAntonietta Bacchiocchi
Antonietta Bacchiocchi
NENoah Earland
Noah Earland
ANAaron M. Newman
Aaron M. Newman

7 May 2013 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MVMatthew D. Vesely
Matthew D. Vesely
RSRobert D. Schreiber
Robert D. Schreiber

15 January 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JSJeremy B. Swann
Jeremy B. Swann
MVMatthew D. Vesely
Matthew D. Vesely
ASAnabel Silva
Anabel Silva
JSJanelle Sharkey
Janelle Sharkey
SAShizuo Akira
Shizuo Akira
MSMark J. Smyth
Mark J. Smyth
Here we report the effects of loss of the Toll-like receptor-associated signaling adaptor myeloid-differentiation factor 88 (MyD88) on tumor induction in two distinct mouse models of carcinogenesis. The 7,12-dimethylbenz[ a ]anthracene (DMBA)/12- O -tetradecanoylphorbol 13-acetate (TPA)-induced skin papilloma model depends on proinflammatory processes, whereas the 3′-methylcholanthrene (MCA) induction of fibrosarcoma has been used by tumor immunologists to illustrate innate and adaptive immune surveillance of cancer. When exposed to a combination of DMBA/TPA, mice lacking MyD88 formed fewer skin papillomas than genetically matched WT controls treated in a similar manner. Unexpectedly, however, fewer MyD88 −/− mice formed sarcomas than WT controls when exposed to MCA. In contrast, MyD88-deficient mice did not show a defective ability to reject highly immunogenic transplanted tumors, including MCA sarcomas. Despite the reported role of TNF in chronic inflammation, TNF-deficient mice were significantly more susceptible to MCA-induced sarcoma than WT mice. Overall, these data not only confirm the key role that MyD88 plays in promoting tumor development but also demonstrate that inflammation-induced carcinogenesis and cancer immunoediting can indeed occur in the same mouse tumor model.